Australia may cut Wegovy from $5,000 a year to $25 a script, for a narrow group

Australia's Pharmaceutical Benefits Advisory Committee recommended in November 2025 that semaglutide, sold as Wegovy, be listed on the Pharmaceutical Benefits Scheme for adults with obesity and established cardiovascular disease — a recommendation the health minister endorsed in January, though the listing depends on price negotiations with manufacturer Novo Nordisk that hadn't concluded as of that endorsement [s1].

Who would actually qualify

The recommended listing covers adults with a body mass index of 35 or higher who have a history of a cardiovascular event — a heart attack or stroke [s1]. For patients of Asian or Indigenous background, the BMI threshold is set lower, at 32.5 [s1] — a population-specific adjustment that reflects established evidence that cardiovascular and metabolic risk can climb at lower BMI thresholds in some population groups than the general thresholds developed from majority-white study populations historically. Health Minister Mark Butler was direct about why the criteria are this narrow rather than covering obesity more broadly: "This is not just a health issue for us, it's also an equity issue," while separately acknowledging a subsidized listing would mean "a very big bill for taxpayers" [s1]. Dr. Mark Mellor, a clinician quoted in the same reporting, said the eligibility criteria were "deliberately narrow" specifically to avoid cost overruns [s1] — meaning the restrictive scope isn't a clinical judgment about who benefits from the drug, it's a budget constraint on top of one.

The price gap this would actually close

Australians currently paying full price for Wegovy face costs of $4,000 to $5,000 a year [s1]. Under a PBS listing, that would drop to the standard general-patient co-payment — $25 per script as of a separate, broader PBS reform that took effect 1 January 2026, cutting the general co-payment down from $31.60 [s2] — or $7.70 for concession card holders [s1]. That $25 figure isn't specific to Wegovy; it's the general PBS co-payment amount every listed medicine carries for non-concession patients, meaning Wegovy would simply become subject to the same nationwide pricing structure as any other subsidized drug, rather than getting a special discount of its own.

Why the timeline is still genuinely open

As of the reporting here, negotiations between the government and Novo Nordisk over the actual subsidized price hadn't begun, and the health minister's office declined to provide even an approximate cost estimate, saying only that a clearer picture would emerge once negotiations started [s1]. A PBAC recommendation and a minister's endorsement are necessary steps toward a PBS listing, but they aren't the listing itself — the price Australia's government actually pays Novo Nordisk, negotiated separately and not yet public, is what determines both the final taxpayer cost and, practically, how quickly the listing can be finalized and take effect.

What this doesn't cover

This recommended listing is scoped specifically to obesity with existing cardiovascular disease — it would not, on its own, extend subsidized access to the much larger population of Australians with obesity but no cardiovascular event history, over 400,000 of whom are reported to already be paying market price for GLP-1 drugs [s1]. Separately, the government has signaled it's reviewing broader access criteria, but that review's own recommendations and timeline are distinct from, and later than, this cardiovascular-specific pathway.

What to watch next

Whether price negotiations with Novo Nordisk conclude and at what price, since that determines both when the listing actually takes effect and how large a taxpayer cost the government absorbs — and separately, what the broader equitable-access review recommends for the much larger group of Australians with obesity outside the current cardiovascular-specific criteria.